{"protocolSection": {"identificationModule": {"nctId": "NCT01217307", "orgStudyIdInfo": {"id": "GIPS-III 2010B257"}, "organization": {"fullName": "University Medical Center Groningen", "class": "OTHER"}, "briefTitle": "Metformin to Reduce Heart Failure After Myocardial Infarction", "officialTitle": "Metabolic Modulation With Metformin to Reduce Heart Failure After Acute Myocardial Infarction: Glycometabolic Intervention as Adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III): a Randomized Controlled Trial.", "acronym": "GIPS-III"}, "statusModule": {"statusVerifiedDate": "2017-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-01"}, "primaryCompletionDateStruct": {"date": "2013-10", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-10", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-10-07", "studyFirstSubmitQcDate": "2010-10-07", "studyFirstPostDateStruct": {"date": "2010-10-08", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-07-31", "resultsFirstSubmitQcDate": "2017-07-31", "resultsFirstPostDateStruct": {"date": "2018-01-30", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2017-07-31", "lastUpdatePostDateStruct": {"date": "2018-01-30", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Chris Lexis", "investigatorTitle": "Drs.", "investigatorAffiliation": "University Medical Center Groningen"}, "leadSponsor": {"name": "University Medical Center Groningen", "class": "OTHER"}, "collaborators": [{"name": "ZonMw: The Netherlands Organisation for Health Research and Development", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The investigators will evaluate the effect of metformin therapy during 4 months in non-diabetic patients following ST-elevation myocardial infarction on left ventricular ejection fraction as measured with cardiac magnetic resonance imaging, compared to placebo.", "detailedDescription": "In this trial, the investigators will evaluate the effect of metformin therapy following ST-elevation myocardial infarction (STEMI) in a total of 380 non-diabetic patients. This trial is a randomized, double blind, controlled trial. The intervention, which consist of metformin 500mg twice daily or placebo twice daily, will commence within three hours after the percutaneous coronary intervention, and will be continued for 4 months. The primary endpoint is the difference between the two intervention groups (metformin vs placebo) in left ventricular ejection fraction, as measured with magnetic resonance imaging after 4 months. The investigators hypothesize that metformin therapy results in a significantly higher ejection fraction in this population."}, "conditionsModule": {"conditions": ["ST Elevation Myocardial Infarction (STEMI)", "Coronary Artery Disease", "Heart Failure", "Diabetes"], "keywords": ["Metformin", "ST elevation myocardial infarction (STEMI)", "Coronary artery disease", "Heart failure", "Diabetes"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2", "PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 380, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Metformin", "type": "EXPERIMENTAL", "description": "metformin 500mg twice daily during 4 months", "interventionNames": ["Drug: Metformin"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo twice daily during 4 months", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Metformin", "description": "Metformin 500mg twice daily during 4 months", "armGroupLabels": ["Metformin"], "otherNames": ["Glucophage"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo twice daily during 4 months", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Improvement in Left Ventricular Ejection Fraction", "description": "The primary efficacy parameter of the GIPS-III trial is LVEF measured by cardiac MRI 4 months after randomization, based on an intention-to-treat analysis. It is hypothesized that metformin therapy will result in a higher ejection fraction after 4 months.", "timeFrame": "4 months"}], "secondaryOutcomes": [{"measure": "the Incidence of a Cardiovascular Event", "description": "Cardiovascular events include major cardiac adverse events (MACE; death, recurrent MI, target lesion revascularization), stroke, non-elective hospitalizations for chest pain or heart failure, all recurrent coronary interventions, and internal cardiac defibrillator implantations. Mortality will be divided into cardiac and non-cardiac. Cardiac death will be divided into three categories: heart failure, sudden death and other. A cardiologist will confirm deaths from cardiovascular causes by examining medical records obtained from hospitals and attending physicians or from attending general practitioner if the patient died at home.", "timeFrame": "4 months and longterm follow-up"}, {"measure": "Markers of Heart Failure and Glycometabolic State", "description": "markers of heart failure: neurohormones (e.g. NT-proBNP), renal function (e.g. MDRD); glycometabolic state: e.g. HbA1c.", "timeFrame": "4 months and longterm follow-up"}, {"measure": "Myocardial Infarct Size and Transmural Extent of Infarction as Measured With Cardiac Magnetic Resonance Imaging", "description": "myocardial infarct size and transmural extent of infarction will be measured using Late Gadolinium Enhancement cardiac magnetic imaging", "timeFrame": "4 months after hospitalization"}, {"measure": "Diastolic Function", "description": "echocardiographic analysis of diastolic function", "timeFrame": "4 months"}, {"measure": "Glycometabolic State", "description": "measured by oral glucose tolerance testing and Glycated Hemoglobin according to current criteria", "timeFrame": "4 months and long-term follow-up"}, {"measure": "Cardiac MRI After 4 Months, Per Protocol Analysis", "description": "A per-protocol analysis, excluding patients diagnosed with new onset diabetes and treated with oral antihyperglycemic agents or insulin prior to cardiac MRI, will be performed as a secondary efficacy parameter", "timeFrame": "4 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* The diagnosis acute MI defined by chest pain suggestive for myocardial ischemia for at least 30 minutes, the time from onset of the symptoms less than 12 hours before hospital admission, and an ECG recording with ST- segment elevation of more than 0.1 mV in 2 or more leads.\n* Successful primary PCI (post-procedural TIMI 2/3);\n* At least one stent sized \u2265 3.0 mm;\n* Eligible for 3T CMR imaging;\n* Verbal followed by written informed consent.\n\nExclusion Criteria:\n\n* rescue PCI after thrombolytic therapy;\n* need for emergency coronary artery bypass grafting;\n* creatinin \\>177 \u03bcmol/L measured pre-PCI;\n* Younger than 18 years;\n* Mechanical ventilation;\n* Diabetes;\n* Prior myocardial infarction;\n* Contra-indication to metformin (see safety);\n* The existence of a life-threatening disease with a life-expectancy of less than 6 months.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Iwan CC van der Horst, MD, PhD", "affiliation": "Thorax Centre, University Medical Centre Groningen", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "University Medical Center Groningen", "city": "Groningen", "zip": "9700RB", "country": "Netherlands", "geoPoint": {"lat": 53.21917, "lon": 6.56667}}]}, "referencesModule": {"references": [{"pmid": "34593124", "type": "DERIVED", "citation": "de Koning MLY, Westenbrink BD, Assa S, Garcia E, Connelly MA, van Veldhuisen DJ, Dullaart RPF, Lipsic E, van der Harst P. Association of Circulating Ketone Bodies With Functional Outcomes After ST-Segment Elevation Myocardial Infarction. J Am Coll Cardiol. 2021 Oct 5;78(14):1421-1432. doi: 10.1016/j.jacc.2021.07.054."}, {"pmid": "28755285", "type": "DERIVED", "citation": "Hartman MHT, Prins JKB, Schurer RAJ, Lipsic E, Lexis CPH, van der Horst-Schrivers ANA, van Veldhuisen DJ, van der Horst ICC, van der Harst P. Two-year follow-up of 4 months metformin treatment vs. placebo in ST-elevation myocardial infarction: data from the GIPS-III RCT. Clin Res Cardiol. 2017 Dec;106(12):939-946. doi: 10.1007/s00392-017-1140-z. Epub 2017 Jul 28."}, {"pmid": "28100626", "type": "DERIVED", "citation": "Eppinga RN, Kofink D, Dullaart RP, Dalmeijer GW, Lipsic E, van Veldhuisen DJ, van der Horst IC, Asselbergs FW, van der Harst P. Effect of Metformin on Metabolites and Relation With Myocardial Infarct Size and Left Ventricular Ejection Fraction After Myocardial Infarction. Circ Cardiovasc Genet. 2017 Feb;10(1):e001564. doi: 10.1161/CIRCGENETICS.116.001564."}, {"pmid": "26808474", "type": "DERIVED", "citation": "Eppinga RN, Hartman MH, van Veldhuisen DJ, Lexis CP, Connelly MA, Lipsic E, van der Horst IC, van der Harst P, Dullaart RP. Effect of Metformin Treatment on Lipoprotein Subfractions in Non-Diabetic Patients with Acute Myocardial Infarction: A Glycometabolic Intervention as Adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III) Trial. PLoS One. 2016 Jan 25;11(1):e0145719. doi: 10.1371/journal.pone.0145719. eCollection 2016."}, {"pmid": "26688733", "type": "DERIVED", "citation": "Lexis CP, van der Horst-Schrivers AN, Lipsic E, Valente MA, Muller Kobold AC, de Boer RA, van Veldhuisen DJ, van der Harst P, van der Horst IC. The effect of metformin on cardiovascular risk profile in patients without diabetes presenting with acute myocardial infarction: data from the Glycometabolic Intervention as adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III) trial. BMJ Open Diabetes Res Care. 2015 Dec 11;3(1):e000090. doi: 10.1136/bmjdrc-2015-000090. eCollection 2015."}, {"pmid": "24687169", "type": "DERIVED", "citation": "Lexis CP, van der Horst IC, Lipsic E, Wieringa WG, de Boer RA, van den Heuvel AF, van der Werf HW, Schurer RA, Pundziute G, Tan ES, Nieuwland W, Willemsen HM, Dorhout B, Molmans BH, van der Horst-Schrivers AN, Wolffenbuttel BH, ter Horst GJ, van Rossum AC, Tijssen JG, Hillege HL, de Smet BJ, van der Harst P, van Veldhuisen DJ; GIPS-III Investigators. Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial. JAMA. 2014 Apr 16;311(15):1526-35. doi: 10.1001/jama.2014.3315."}, {"pmid": "22968678", "type": "DERIVED", "citation": "Lexis CP, van der Horst IC, Lipsic E, van der Harst P, van der Horst-Schrivers AN, Wolffenbuttel BH, de Boer RA, van Rossum AC, van Veldhuisen DJ, de Smet BJ; GIPS-III Investigators. Metformin in non-diabetic patients presenting with ST elevation myocardial infarction: rationale and design of the glycometabolic intervention as adjunct to primary percutaneous intervention in ST elevation myocardial infarction (GIPS)-III trial. Cardiovasc Drugs Ther. 2012 Oct;26(5):417-26. doi: 10.1007/s10557-012-6413-1."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Metformin", "description": "metformin 500mg twice daily during 4 months\n\nMetformin: Metformin 500mg twice daily during 4 months"}, {"id": "FG001", "title": "Placebo", "description": "Placebo twice daily during 4 months\n\nPlacebo: Placebo twice daily during 4 months"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "191"}, {"groupId": "FG001", "numSubjects": "189"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "191"}, {"groupId": "FG001", "numSubjects": "188"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Metformin", "description": "metformin 500mg twice daily during 4 months\n\nMetformin: Metformin 500mg twice daily during 4 months"}, {"id": "BG001", "title": "Placebo", "description": "Placebo twice daily during 4 months\n\nPlacebo: Placebo twice daily during 4 months"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "191"}, {"groupId": "BG001", "value": "189"}, {"groupId": "BG002", "value": "380"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "58.7", "spread": "11.8"}, {"groupId": "BG001", "value": "58.8", "spread": "11.5"}, {"groupId": "BG002", "value": "58.8", "spread": "11.6"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "47"}, {"groupId": "BG001", "value": "48"}, {"groupId": "BG002", "value": "95"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "144"}, {"groupId": "BG001", "value": "141"}, {"groupId": "BG002", "value": "285"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Improvement in Left Ventricular Ejection Fraction", "description": "The primary efficacy parameter of the GIPS-III trial is LVEF measured by cardiac MRI 4 months after randomization, based on an intention-to-treat analysis. It is hypothesized that metformin therapy will result in a higher ejection fraction after 4 months.", "populationDescription": "patients undergoing primary percutaneous coronary intervention (PCI) for STEMI", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "% of LVEF", "timeFrame": "4 months", "groups": [{"id": "OG000", "title": "Metformin", "description": "metformin 500mg twice daily during 4 months\n\nMetformin: Metformin 500mg twice daily during 4 months"}, {"id": "OG001", "title": "Placebo", "description": "Placebo twice daily during 4 months\n\nPlacebo: Placebo twice daily during 4 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "191"}, {"groupId": "OG001", "value": "189"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "53.1", "lowerLimit": "51.6", "upperLimit": "54.6"}, {"groupId": "OG001", "value": "54.8", "lowerLimit": "53.5", "upperLimit": "56.1"}]}]}]}, {"type": "SECONDARY", "title": "the Incidence of a Cardiovascular Event", "description": "Cardiovascular events include major cardiac adverse events (MACE; death, recurrent MI, target lesion revascularization), stroke, non-elective hospitalizations for chest pain or heart failure, all recurrent coronary interventions, and internal cardiac defibrillator implantations. Mortality will be divided into cardiac and non-cardiac. Cardiac death will be divided into three categories: heart failure, sudden death and other. A cardiologist will confirm deaths from cardiovascular causes by examining medical records obtained from hospitals and attending physicians or from attending general practitioner if the patient died at home.", "reportingStatus": "NOT_POSTED", "timeFrame": "4 months and longterm follow-up", "denomUnitsSelected": "Participants"}, {"type": "SECONDARY", "title": "Markers of Heart Failure and Glycometabolic State", "description": "markers of heart failure: neurohormones (e.g. NT-proBNP), renal function (e.g. MDRD); glycometabolic state: e.g. HbA1c.", "reportingStatus": "NOT_POSTED", "timeFrame": "4 months and longterm follow-up", "denomUnitsSelected": "Participants"}, {"type": "SECONDARY", "title": "Myocardial Infarct Size and Transmural Extent of Infarction as Measured With Cardiac Magnetic Resonance Imaging", "description": "myocardial infarct size and transmural extent of infarction will be measured using Late Gadolinium Enhancement cardiac magnetic imaging", "reportingStatus": "NOT_POSTED", "timeFrame": "4 months after hospitalization", "denomUnitsSelected": "Participants"}, {"type": "SECONDARY", "title": "Diastolic Function", "description": "echocardiographic analysis of diastolic function", "reportingStatus": "NOT_POSTED", "timeFrame": "4 months", "denomUnitsSelected": "Participants"}, {"type": "SECONDARY", "title": "Glycometabolic State", "description": "measured by oral glucose tolerance testing and Glycated Hemoglobin according to current criteria", "reportingStatus": "NOT_POSTED", "timeFrame": "4 months and long-term follow-up", "denomUnitsSelected": "Participants"}, {"type": "SECONDARY", "title": "Cardiac MRI After 4 Months, Per Protocol Analysis", "description": "A per-protocol analysis, excluding patients diagnosed with new onset diabetes and treated with oral antihyperglycemic agents or insulin prior to cardiac MRI, will be performed as a secondary efficacy parameter", "reportingStatus": "NOT_POSTED", "timeFrame": "4 months", "denomUnitsSelected": "Participants"}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Metformin", "description": "metformin 500mg twice daily during 4 months\n\nMetformin: Metformin 500mg twice daily during 4 months", "deathsNumAffected": 3, "deathsNumAtRisk": 191, "seriousNumAffected": 11, "seriousNumAtRisk": 191, "otherNumAffected": 73, "otherNumAtRisk": 191}, {"id": "EG001", "title": "Placebo", "description": "Placebo twice daily during 4 months\n\nPlacebo: Placebo twice daily during 4 months", "deathsNumAffected": 1, "deathsNumAtRisk": 188, "seriousNumAffected": 6, "seriousNumAtRisk": 188, "otherNumAffected": 51, "otherNumAtRisk": 188}], "seriousEvents": [{"term": "Reinfarction", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 8, "numAtRisk": 191}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 188}]}, {"term": "Cardiovascular death", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 191}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 188}]}, {"term": "Target lesion revascularization", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 191}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 188}]}], "otherEvents": [{"term": "Non-target lesion revascularization", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 40, "numAffected": 40, "numAtRisk": 191}, {"groupId": "EG001", "numEvents": 26, "numAffected": 26, "numAtRisk": 188}]}, {"term": "CABG", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 10, "numAffected": 10, "numAtRisk": 191}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 188}]}, {"term": "Hospitalization for chest pain", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 23, "numAffected": 23, "numAtRisk": 191}, {"groupId": "EG001", "numEvents": 20, "numAffected": 20, "numAtRisk": 188}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Dr. I.C.C. van der Horst", "organization": "University Medical Center Groningen", "email": "i.c.c.van.der.horst@umcg.nl"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}, {"id": "D000003324", "term": "Coronary Artery Disease"}, {"id": "D000017202", "term": "Myocardial Ischemia"}, {"id": "D000003327", "term": "Coronary Disease"}, {"id": "D000009203", "term": "Myocardial Infarction"}, {"id": "D000072657", "term": "ST Elevation Myocardial Infarction"}, {"id": "D000007238", "term": "Infarction"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000007511", "term": "Ischemia"}, {"id": "D000010335", "term": "Pathologic Processes"}, {"id": "D000009336", "term": "Necrosis"}, {"id": "D000001161", "term": "Arteriosclerosis"}, {"id": "D000001157", "term": "Arterial Occlusive Diseases"}, {"id": "D000014652", "term": "Vascular Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "relevance": "LOW"}, {"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M12155", "name": "Myocardial Infarction", "asFound": "Myocardial Infarction", "relevance": "HIGH"}, {"id": "M1072", "name": "ST Elevation Myocardial Infarction", "asFound": "ST Elevation Myocardial Infarction", "relevance": "HIGH"}, {"id": "M10282", "name": "Infarction", "asFound": "Infarction", "relevance": "HIGH"}, {"id": "M6546", "name": "Coronary Artery Disease", "asFound": "Coronary Artery Disease", "relevance": "HIGH"}, {"id": "M19506", "name": "Myocardial Ischemia", "asFound": "Coronary Artery Disease", "relevance": "HIGH"}, {"id": "M6549", "name": "Coronary Disease", "asFound": "Coronary Artery Disease", "relevance": "HIGH"}, {"id": "M10543", "name": "Ischemia", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "M12284", "name": "Necrosis", "relevance": "LOW"}, {"id": "M4469", "name": "Arteriosclerosis", "relevance": "LOW"}, {"id": "M4465", "name": "Arterial Occlusive Diseases", "relevance": "LOW"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}, {"id": "T170", "name": "Acute Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}